Trial Profile
A Phase I/II Study to Evaluate the Safety and Efficacy of Allogeneic Infusion of Adipose-Derived Stem Cells in Moderate to Severe Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Adipose-derived stem cells-UnicoCell (Primary)
- Indications Renal failure
- Focus Adverse reactions; Therapeutic Use
- Sponsors UnicoCell Biomed
- 06 Feb 2024 Status changed from recruiting to completed.
- 12 Aug 2020 Study design was changed. Planned number of patients increased from 36 to 90
- 07 Aug 2020 Planned number of patients changed from 36 to 90.